Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Im ersten Live-Webinar unserer neuen Veranstaltungsreihe im Rahmen der Initiative DiAd gegen gegen Typ-2-Diabetes und Adipositas von Springer Medizin am 13. Juni von 17.30 bis 19 Uhr werfen wir einen interdisziplinären Blick auf die Herausforderungen und Chancen in der Primärversorgung von Menschen mit Adipositas und beleuchten auch die Perspektive der Betroffenen. Jetzt hier kostenlos anmelden und 2 CME-Punkte einsammeln.
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 8/2011

01.11.2011 | Substantive Review

A Systematic Review of the Psychiatric Side-Effects of Efavirenz

verfasst von: Christopher A. Kenedi, Harold W. Goforth

Erschienen in: AIDS and Behavior | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Concerns regarding the use of efavirenz in patients with a history of mental illness may predispose clinicians to not offer this agent to psychiatrically ill populations in spite of the convenience of once daily dosing, which can result in improved adherence in these at-risk populations. This systematic review examines the current data regarding the neuropsychiatric effects of efavirenz, and also attempts to provide guidance to clinicians using efavirenz to treat patients with mental illness. The review identified high rates of neuropsychiatric side effects including vivid dreams, insomnia and mood changes in approximately 50% of patients who initiate efavirenz. The effects begin quickly, commonly peak in the first 2 weeks, and are generally mild and transient in nature. Isolated case reports and uncontrolled data suggest higher rates of severe side effects; however, there is no clear evidence of a broadly increased risk of suicide or dangerous behavior for patients taking efavirenz as part of their antiretroviral regimen.
Literatur
1.
Gallant JE, DeJesus E, Arribas JR, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–60.PubMedCrossRef
2.
Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis. 2003;36(9):1186–90.PubMedCrossRef
3.
Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007;8(6):851–71.PubMedCrossRef
4.
Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available from http://​AIDSinfo.​nih.​gov. Cited Accessed, 1 May 2009.
5.
6.
Ruiz N. Clinical history of efavirenz. Int J Clin Pract Suppl. 1999;103:3–7.PubMed
7.
Moyle G. In: 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 17–21, 2002.
8.
Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009;11(2):103–9.PubMed
9.
Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29(3):244–53.PubMed
10.
Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009;151(3):149–56.PubMed
11.
Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7(8):544–8.PubMedCrossRef
12.
Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25):1865–73.PubMedCrossRef
13.
Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38(5):560–5.PubMedCrossRef
14.
Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714–21.PubMed
15.
Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003;188(5):625–34.PubMedCrossRef
16.
Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials. 2002;3(4):279–86.PubMedCrossRef
17.
18.
AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2008. p. 701.
19.
Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):257–64.PubMedCrossRef
20.
Goldenberg D. Psychiatric and neuropsychiatric manifestations of HIV infection. J Int Assoc Physicians AIDS Care (Chic Ill). 2003;2(2):88. author reply 9-90.CrossRef
21.
Wanchu APS, Bambery P, Singh S, Varma S. Adverse drug reactions to generic antiretroviral medications in resource constrained set- tings: implication for scaling up therapy. In: Paper presented at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006 (abstract 562).
22.
Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4(1):62–6.PubMedCrossRef
23.
Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42(12):1790–9.PubMedCrossRef
24.
O’Mahony SM, Myint AM, Steinbusch H, et al. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12(5):293–8.PubMedCrossRef
25.
Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med. 2003;4(3):302–4.PubMedCrossRef
26.
Damsa C, Bandelier C, Maris S, et al. Recurrence of post-traumatic stress disorder and antiretrovirals. Scand J Infect Dis. 2005;37(4):313–6.PubMedCrossRef
27.
Shah MD, Balderson K. A manic episode associated with efavirenz therapy for HIV infection. AIDS. 2003;17(11):1713–4.PubMedCrossRef
28.
Peyriere H, Mauboussin JM, Rouanet I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001;15(10):1323–4.PubMedCrossRef
29.
Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis. 2004;38(3):430–2.PubMedCrossRef
30.
Tashima K, Staszewski S, Nelson M, et al. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. 2008;22(2):275–9.PubMedCrossRef
31.
Faggian F, Lattuada E, Lanzafame M, et al. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. AIDS Care. 2005;17(7):908–10.PubMedCrossRef
32.
Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials. 2003;4(3):145–9.PubMedCrossRef
33.
Garey M, editor. Efavirenz (EFV) tolerability in the real world: relation to mental illness, alcohol, and illicit drug use in a large, urban HIV clinic. In: Presented at the XIII international AIDS conference, Durban, SA, July 9–14, 2000 (abstract no. WePeB4288).
34.
Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51(3):213–7.PubMedCrossRef
35.
36.
Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2008;49(1):61–3.PubMedCrossRef
37.
Bickel M, Stephan C, Rottmann C, et al. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J Infect Dis. 2005;37(6–7):520–2.PubMedCrossRef
38.
Gill MJ, Rachlis A, Walmsley S, et al. Canadian Expert Panel recommendations on the management of CNS symptoms related to efavirenz. Can J Infect Dis. 2001;12:20c–30c.
39.
Skeie L, Maeland A. Can efavirenz be taken in the morning? Scand J Infect Dis. 2006;38(11–12):1089–91.PubMedCrossRef
40.
Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2005;10(4):489–98.PubMed
41.
Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391–400.PubMed
42.
van Luin M, Brouwer AM, van der Ven A, et al. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS. 2009;23(6):742–4.PubMedCrossRef
43.
Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr. 2006;43(3):284–92.PubMedCrossRef
44.
Martinez-Picado J, Negredo E, Ruiz L, et al. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med. 2003;139(2):81–9.PubMed
45.
Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011–9.PubMedCrossRef
46.
van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253–63.PubMedCrossRef
47.
Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6(4):187–96.PubMedCrossRef
48.
Spire B, Carrieri P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16(5):558–64.PubMedCrossRef
49.
Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27(4):336–43.PubMedCrossRef
50.
Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr. 2006;42(4):514–5.PubMedCrossRef
51.
Brokaw DK, Fulco PP, Klinger R. Efavirenz use in HIV infected patients with a psychiatric history. In: Presented at the 35th American Society of Health-System Pharmacists annual mid-year clinical meeting, Las Vegas, NV, December 3–7, 2000.
52.
Gaughan DM, Hughes MD, Oleske JM, et al. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics. 2004;113(6):e544–51.PubMedCrossRef
53.
Goldenberg D, Boyle B, Vaamonde C, et al., editors. Psychiatric illness and efavirenz study (PIES). In: Presented at the XIII international AIDS conference, Durban, SA, July 9–14, 2000.
54.
Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8(5):318–22.CrossRef
55.
Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20(8):542–8.PubMedCrossRef
56.
Welch KJ, Morse A. Association between efavirenz and selected psychiatric and neurological conditions. J Infect Dis. 2002;85(2):268–9.CrossRef
57.
Koppel BS, Bharel C. Use of amitriptyline to offset sleep disturbances caused by efavirenz. AIDS Patient Care STDS. 2005;19(7):419–20.PubMedCrossRef
58.
de la Garza C, Paoletti-Duarte, García-Martín, et al. Efavirenz-induced psychosis. AIDS. 2001;15(14):1911–2.CrossRef
59.
Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45(10):e128–30.PubMedCrossRef
60.
Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005;40(3):e22–3.PubMedCrossRef
61.
Poulsen HD, Lublin HK. Efavirenz-induced psychosis leading to involuntary detention. AIDS. 2003;17(3):451–3.PubMedCrossRef
62.
Allavena C, Le Moal G, Michau C, et al. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther. 2006;11(2):263–5.PubMed
63.
Dawson S, Woods C. Neuropsychiatric effects of efavirenz: delayed onset. Int J STD AIDS. 2005;16(11):769–70.PubMedCrossRef
64.
Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22(7):930–3.PubMedCrossRef
65.
Sabato S, Wesselingh S, Fuller A, et al. Efavirenz-induced catatonia. AIDS. 2002;16(13):1841–2.PubMedCrossRef
66.
Blanch J, Corbella B, Garcia F, et al. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001;33(2):270–1.PubMedCrossRef
67.
Boscacci RT, Buclin T, Furrer H, et al. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006;20(9):1352–4.PubMedCrossRef
Metadaten
Titel
A Systematic Review of the Psychiatric Side-Effects of Efavirenz
verfasst von
Christopher A. Kenedi
Harold W. Goforth
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 8/2011
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9939-5

Weitere Artikel der Ausgabe 8/2011

AIDS and Behavior 8/2011 Zur Ausgabe

Original Paper

Evaluation of a Peer Network-Based Sexual Risk Reduction Intervention for Men in Beer Halls in Zimbabwe: Results from a Randomized Controlled Trial

Original Paper

The Relationship of Manic Episodes and Drug Abuse to Sexual Risk Behavior in Patients with Co-Occurring Bipolar and Substance Use Disorders: a 15-Month Prospective Analysis

Original Paper

Can Peer Education Make a Difference? Evaluation of a South African Adolescent Peer Education Program to Promote Sexual and Reproductive Health

Original Paper

Adolescent Health-Risk Sexual Behaviors: Effects of a Drug Abuse Intervention

Original Paper

Impact of a mHealth Intervention for Peer Health Workers on AIDS Care in Rural Uganda: A Mixed Methods Evaluation of a Cluster-Randomized Trial

Original Paper

Evaluation of an HIV Prevention Intervention for African Americans and Hispanics: Findings from the VOICES/VOCES Community-Based Organization Behavioral Outcomes Project

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise